| A1† / 2012 / Multicenter |
Diagnosis
Imaging tests used in diffuse large B-cell lymphoma, such as computed tomography and positron emission tomography.
|
| A2† / 2017 / United States of America |
| A3† / 2016 / Italy |
| A4† / 2016 / Colombia |
Diagnosis
Use of gene expression profiling to assess molecular profiling at the time of diagnosis and guide therapeutic decisions, such as next-generation sequencing.
|
| A5† / 2017 / United States of America |
| A6† / 2019 / Austria |
| A7† / 2018 / United States of America |
| A8† / 2019 / Multicenter |
| A9† / 2020 / Denmark |
| A10† / 2016 / United States of America |
| A11† / 2017 / Brazil |
Diagnosis
Clinical techniques, biopsies, complete blood count and differential counts, immunology tests, flow cytometry, radiological tests and genetic technologies such as chromosome analysis and DNA sequencing‡.
|
| A12† / 2018 / European countries |
| A13† / 2021 / United Kingdom |
Diagnosis
Triple assessment based on clinical examination, imaging and biopsy.
|
|
Treatment
Surgery is the recommended primary treatment. Mass-forming disease, lymph node involvement, or distant disease may require systemic treatment, with indication for chemotherapy, monoclonal antibody, and/or autologous stem cell transplantation. Radiotherapy should be considered when complete excision is not possible, if surgical margins are positive despite total capsulectomy, or when there is chest wall invasion.
|
| A14† / 2020 / South Korea |
Diagnosis
Use of artificial intelligence-based algorithm for screening patients with suspected hematologic malignancies using cell population data generated by routine complete blood count.
|
| A15† / 2012 / Germany |
Diagnosis
Investigation of central nervous system involvement in the diagnosis of acute myeloid leukemia is considered necessary in children.
|
|
Diagnosis
Additional tests in diagnosis are medical history, performance status, physical examination, syndromes, comorbidities, biochemistry, clotting tests, serum pregnancy test in women of childbearing potential, hepatitis A, B, C, blood group, chest, 12-lead, electrocardiography, echocardiography.
|
|
Treatment
Central nervous system treatment is administered to all pediatric patients, including those who have no detectable central nervous system involvement.
|
|
Treatment
Hematopoietic stem cell transplantation is used as post-remission consolidation therapy.
|
| A16† / 2016 / Multicenter |
Treatment
There is continued indication for allogeneic stem cell transplantation for acute myeloid leukemia, myeloproliferative neoplasia and bone marrow failure, and indication of autologous transplantation in myeloma.
|
| A17† / 2015 / Iran |
| A18† / 2017 / United States of America |
Treatment
Allogeneic hematopoietic stem cell transplantation is a treatment option for patients with relapsed and refractory T-cell lymphoma. It should be considered early, in most cases after the first recurrence, since advanced disease and multiple previous therapies predict a higher risk of non-relapse-related mortality and higher recurrence rates.
|
| A19† / 2018 / Germany |
| A20† / 2022 / England |
Treatment
Patients under 60 years of age are usually treated with standard induction intensive polychemotherapy, followed by intensive consolidation therapy after remission is achieved. May be associated with hematopoietic stem cell transplantation.
|
| A21† / 2019 / United States of America |
| A22† / 2019 / United States of America |
| A23† / 2011 / Italy |
| A24† / 2008 / Italy |
| A25† / 2007 / United States of America |
| A26† / 2013 / Austria |
| A27† / 2014 / Austria |
| A28† / 2016 / China |
| A29† / 2016 / United States of America |
| A30† / 2017 / South Korea |
| A31† / 2018 / Turkey |
| A32† / 2017 / South Korea |
| A33† / 2018 / Finland |
| A34† / 2019 / China |
| A35† / 1978 / United States of America |
| A36† / 2018 / United States of America |
| A37† / 2018 / France |
Treatment
Rescue chemotherapy in case of refractory hematologic malignancies.
|
| A38† / 2019 / United States of America |
Treatment
Pregnant women - fetal toxicity occurs from cytostatic therapy groups during the first trimester, while chemotherapy can be safely administered during the second and/or third trimester and the combination of daunorubicin and cytarabine is recommended for induction. All tyrosine kinase inhibitors are teratogenic and are contraindicated during pregnancy.
|
| A39† / 2020 / European countries |
| A40† / 2020 / Italy |
| A41† / 2017/ Italy |
| A42† / 2019 / Taiwan |
Treatment
Brentuximab vedotin, antibody-drug conjugate, is well tolerated and effective in the treatment of Asian patients with relapsed and refractory Hodgkin’s lymphoma. It can strengthen disease control before transplantation and improve post-transplant outcomes, even among heavily pretreated patients.
|
| A43† / 2018 / China |
Treatment
Use of single-mode radiotherapy only in early stages of HL and low-grade NHL.
In advanced stage patients, cycles of chemotherapy followed by radiotherapy can be associated.
Radiation therapy appeared to improve local control, which suggests that it may be a better choice for therapy when trying to balance treatment efficacy and tolerability.
|
| A44† / 2004 / Australia |
| A45† / 2016 / Switzerland |
| A46† / 2017 / Italy |
| A47† / 2020 / Italy |
| A48† / 2020 / Italy |
| A49† / 2017 / United States of America |
| A50† / 2014 / Netherlands |
Treatment
Older adults - patients should be encouraged to make decisions based on accurate information about the risks and benefits of all available treatment options, including investigational clinical trial drugs.
|
| A51† / 2017 / China |
Treatment
Immunotherapy is a safe, viable and well-tolerated treatment for patients with multiple myeloma and may be a promising strategy for relapsed or refractory cases.
|
| A52† / 2015 / China |
| A53† / 2019 / United States of America |
Treatment
Immunotherapies are at an investigation stage, but present an attractive means to develop a multimodal therapy with the potential for improved therapeutic efficacy.
|
| A54† / 2013 / Iran |
| A55† / 2018 / United States of America |
| A56† / 2019 / Canada |
| A57† / 2020 / United States of America |
| A58† / 2021 / Ireland |
| A59† / 2019 / United States of America |
Treatment
Older adults - an individualized and personalized approach to administering intensive therapies to older adults with hematologic disorders, with the options of intensive induction chemotherapy, hypomelting agents, allogeneic and autologous hematopoietic cell transplantation.
|
| A60† / 2013 / Italy |
| A61† / 2012 / France |
Treatment
Older adults - comprehensive geriatric assessment to determine eligibility for treatment, including functional status, comorbidities, cognition, psychological or mental health, social support, nutritional status, and polypharmacy.
|
| A62† / 2007 / Switzerland |
| A63† / 2019 / United States of America |
| A64† / 2014 / Multicenter |
Support
Dental - comprehensive dental and oral assessment to identify and eliminate possible sources of infection, pain and trauma, such as teeth compromised by caries, in addition to pain control, maintenance of oral function, management of oral complications resulting from treatment and conservation of quality of life.
|
|
Support
Dental - guidance on brushing three times a day, using ultra-soft brushes, as well as care with brush hygiene and conservation, in addition to frequent rinsing, especially in situations where hygiene is hampered by oral mucositis.
|
|
Support
Dental - use topical analgesics or anesthetics to relieve pain from oral mucositis.
|
|
Support
Dental - management of oral complications of chemotherapy/stem cell transplantation, such as encouraging the patient to maintain oral intake while suffering from dysgeusia. Maintenance of oral function, such as moistening the mouth with sips and sprays of water or saliva substitutes and mechanical flavor stimulants (chewing gum, sweet and sour candies) and the use of spray or mouthwash.
|
| A65† / 1996 / United States of America |
Support
Dental - elimination of potential sources of oral trauma, such as ill-fitting dentures, orthodontic appliances, poor/rough restorations, traumatic dentition and dental calculus.
|
| A66† / 2015 / Brazil |
| A67† / 2013 / Japan |
Support
Dental - chemotherapy grading tool that induces myelosuppression, to facilitate communication between the medical and dental team and the treatment of odontogenic infection triggered by therapy.
|
| A68† / 2003 / United States of America |
Support
Multidisciplinary - screening of symptoms and appropriate intervention, from the implementation of interviews, referrals, coordination and monitoring of nursing. Specialist assessments as part of the initial routine regarding the practice of social service and psychology.
|
| A69† / 2020 / Germany |
| A70† / 2019 / United States of America |
Support
Changes in policies for early admission to the Intensive Care Unit for the care of infections in patients with hematopoietic malignancies.
|
| A71† / 2017 / Poland |
Support
Nutritional - act prophylactically, based on the assessment of nutritional status, with the aid of various methods (questionnaires to assess the risk of malnutrition, anthropometric measurements, biochemical tests, among others), and introduce nutrient supplementation by enteral nutrition, by providing oral nutritional supplements or parenteral nutrition, in cases of malnutrition and cachexia already installed.
|
| A72† / 2016 / England |
Support
Use low-dose prophylactic platelet transfusions for thrombocytopenic patients due to myelosuppressive chemotherapy or stem cell transplantation.
|
| A73† / 2015 / China |
Support
Protocol implementation to effectively reduce the door-to-antibiotic time to meet the international standard of care in patients with neutropenic sepsis.
|
| A74† / 2006 / South Korea |
Support
Assessment and management of infections associated with neutropenia, with prophylaxis for bacterial and fungal infections due to patients’ compromised immune status.
|
| A75† / 2012 / United States of America |
| A76† / 2018 / Italy |
| A77† / 2019 / United States of America |
Support
Implementation of yoga therapy protocol in cancer, including body awareness, breathing awareness, adaptive movement, and relaxing imaging practice.
|
| A78† / 2007 / United States of America |
Palliative care
Engage patients in early care planning, which includes the realization of a life will, prognostic discussion, treatment options, and life support treatment preferences.
|
| A79† / 2018 / United States of America |
| A80† / 2020 / United States of America |
Palliative care
Manage symptoms, emotional support, attention to psychosocial and spiritual needs, advanced care planning and care coordination.
|
| A81† / 2015 / Finland |
| A82† / 2017 / Spain |
| A83† / 2015 / United States of America |
| A84† / 2019 / Netherlands |
Palliative care
Timely insert eligible patients into care that promotes quality of life, according to individual preferences.
|
| A85† / 2012 / United States of America |
| A86† / 2020 / Germany |
| A87† / 2014 / Brazil |
| A88† / 2019 / United States of America |
| A89† / 2019 / Saudi Arabia |
Post-treatment
Screen for secondary malignancies or recurrence of cancer, minimization of risk factors and exposures and early intervention, if detected.
|
|
Post-treatment
Assess the persistence of treatment-related toxicity and the risks of late effects.
|
|
Post-treatment
Provide counseling on reproduction and basal fertility assessment, on sperm bank and oocyte bank. In case of sexual dysfunction, perform sex hormone replacement and/or treatment of vaginal dryness.
|
|
Post-treatment
Screen for psychosocial issues such as depression, anxiety, post-traumatic stress disorder, metabolic syndromes such as diabetes, weight gain or loss, dyslipidemia.
|
|
Post-treatment
Generate incentive to preventive health, with the practice of healthy life habits, recommendations for regular physical activity, maintenance of optimal body mass index, vaccination, routine screening for fatigue, routine screening and pain assessment, and sleep hygiene education.
|
| A90† / 2019 / China |
Post-treatment
Monitor minimal residual disease, prevention and treatment of recurrence.
|
| A91† / 2000 / Australia |
Post-treatment
Engage patients in support services, such as educational programs, support and volunteers, to support the return to routine at home and provide support to families.
|
| A92† / 2014 / Australia |
Post-treatment
Apply a research tool for unmet needs of survivors in five areas: financial concerns, emotional health, access and continuity of care, information and relationships.
|
| A93† / 2017 / United States of America |
Post-treatment
Propose care models:
1. Advisory Model
The person responsible for care becomes the primary care health professional, who has advanced oncology practice (nurse, oncologist or primary care physician focused on cancer survival). A survival consultation is held with follow-up visits with the formation of survival care plans, summary of late effects, symptom assessment and quality of life.
2. Shared Service Model
The performance of care is shared between the cancer specialist and the primary care physician. In this relationship, the oncologist provides all cancer-related care in the post-treatment phase, while the risk of disease recurrence is higher. During this period, primary care physicians manage non-cancer care, if applicable. When deemed appropriate, the oncologist releases the patient for primary care, including a written summary of treatment in the transition of care and a survival care plan to help formalize communication channels, delegate responsibilities and ensure adequate medical follow-up.
|
Thumbnail
